Market capitalization | $3.60b |
Enterprise Value | $3.07b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 28.45 |
P/S ratio (TTM) P/S ratio | 33.39 |
P/B ratio (TTM) P/B ratio | 7.83 |
Revenue growth (TTM) Revenue growth | -2.16% |
Revenue (TTM) Revenue | $107.94m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
17 Analysts have issued a Arcellx forecast:
17 Analysts have issued a Arcellx forecast:
Dec '24 |
+/-
%
|
||
Revenue | 108 108 |
2%
2%
|
|
Gross Profit | 103 103 |
5%
5%
|
|
EBITDA | -132 -132 |
52%
52%
|
EBIT (Operating Income) EBIT | -138 -138 |
53%
53%
|
Net Profit | -107 -107 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Rami Elghandour |
Employees | 163 |
Founded | 2014 |
Website | www.arcellx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.